Maryland-based Insilico Medicine recently published research results in Nature Biotechnology that in just 21 days, their AI-based technology was able to determine six possible treatments for fibrosis, and that one of these was already showing promising results on mice. Insilico is on the front edge of AI in drug development, and while they do have some IP, they published the code for this model on GitHub.
Soon after this paper was published, Insilico announced the completion of a massive new Series B funding round, raising $37 million. The funding will primarily be used to increase staff and commercialize current findings. If this model is as promising as the company hopes, it could lead to a large amount of IP in the future.
